Zkacin 500 Injection contains Amikacin sulfate equivalent to 500 mg of Amikacin, a broad-spectrum aminoglycoside antibiotic used primarily for the treatment of serious Gram-negative bacterial infections. It exhibits bactericidal activity by binding irreversibly to the 30S ribosomal subunit, inhibiting protein synthesis and leading to bacterial cell death. Zkacin 500 Injection is indicated for severe infections caused by susceptible strains, including septicemia, lower respiratory tract infections, complicated urinary tract infections, intra-abdominal infections, bone and joint infections, and skin and soft tissue infections. It is particularly useful in cases where resistance to other aminoglycosides or antibiotics is suspected. The injection is administered intramuscularly or intravenously, with dosing adjusted based on the severity of infection, renal function, and patient response. Monitoring of serum drug levels and renal function is recommended to minimize the risk of nephrotoxicity and ototoxicity, which are potential adverse effects associated with aminoglycosides. Zkacin 500 Injection should be used with caution in patients with pre-existing renal impairment, hearing loss, or neuromuscular disorders. It is contraindicated in patients with known hypersensitivity to Amikacin or other aminoglycosides. Proper aseptic technique should be employed during administration to prevent contamination.